Skip to main content

GS-US-419-4016 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

NCT03077412

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Gilead Sciences

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). This study focuses on perianal fistulas, which are a complication of Crohn’s disease. Perianal fistulas occur when a small tunnel develops between the bowel and the skin near the anus. The purpose of this study is to see if filgotinib is effective and safe in treating people with perianal fistulizing Crohn’s disease.